Beyond Air Inc. (XAIR) shares are rising above 25% in pre-market today, after the company announced submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for use of its LungFitTM BRO system in the treatment of COVID-19 patients.
from RTT - Before the Bell https://ift.tt/2xI4vtH
via IFTTT
No comments:
Post a Comment